Article

  • Article

    US Government Poised for Long-Awaited Powers on Drug Pricing
    08.06.2022

    Via Bloomberg: Drugmakers have long said R&D will suffer if prices regulated

  • Article

    HEALTH CARE BRIEFING: Senate Drug Measures Cut Deficit, CBO Says
    08.04.2022

    Via Bloomberg Government: Senate Democrats’ tax, climate, and drug-pricing bill would cut down federal budget deficits by $102 billion over 10 years, the nonpartisan Congressional Budget Office said.

  • Article

    Biotech Investors Sound the Alarm on Senate Drug Pricing Bill
    08.03.2022

    Via the Washington Times: A group of biotech investors and doctors are warning that the Senate’s drug-pricing proposal, aimed at lowering skyrocketing prices, would “strike a huge blow” to patient access and halt research on new treatments for Alzheimer’s disease, heart disease and cancer.

  • Article

    Don’t Look Up? Congress Can’t Ignore Risk to Small Molecule Drugs in Pricing Bill, Investors Warn
    08.03.2022

    A budget-neutral fix that would extend the time before small molecule drugs are subject negotiations but increase the minimum discounts for the products is floated as the pricing legislation moves toward a Senate floor vote.

  • Article

    LTE: Patents protect people’s access to life-saving medicine
    06.05.2022

    See Incubate's letter to the editor about why patents are necessary in protecting patient access.

  • Article

    To Spend Less on Healthcare, Invest in More Medicines
    04.05.2022

    Read John Stanford and JF Formela's op-ed on how we can lower health costs by spending more on drugs.

  • Article

    CMS’s Devastating Blow to Seniors
    02.09.2022

    Read Incubate Advisory Council member Gaurav Gupta's op-ed on the CMS's decision to cover Alzheimer's drugs.

  • Article

    Investors Say Drug-Pricing Measure May Shift Incentives for Biotech Venture Funding
    12.02.2021

    A drug-pricing bill the House passed in November could affect which life-sciences startups venture-capital investors are likely to back.

  • Article

    House passage of Build Back Better gets mixed reaction
    11.22.2021

    As investors in biotechnology and pharmaceuticals, we're alarmed by the potential consequences of the drug-pricing measure included in the Build Back Better Act, which just passed the House.

  • Article

    Regeneron, Janssen Drugs Fit Profile Targeted in Spending Bill
    11.10.2021

    Plan would negotiate prices of expensive older pharmaceuticals Moderate Democrats sought compromise to preserve innovation

  • Article

    Drug pricing bill’s unintended consequences will distort drug development
    11.09.2021

    The ultimate victims of all the unintended consequences of the current proposal will be all of us as future patients.

  • Article

    Leading Venture Capital Group Concerned with Prescription Drug Deal
    11.04.2021

    Investors in biotechnology and pharmaceuticals aere concerned about the potential consequences of the new drug-pricing legislation before Congress in the Build Back Better Act.